NASDAQ: DCOYDecoy Therapeutics Inc Stock
$0.82+0.05 (+6.49%)
Updated Jan 9, 2026
DCOY Price
$0.82
Fair Value Price
N/A
Market Cap
$4.81M
52 Week Low
$0.52
52 Week High
$108.00
P/E
-0.02x
P/B
1.13x
P/S
N/A
PEG
N/A
Dividend Yield
N/A
Revenue
$0.00
Earnings
-$5.00M
Gross Margin
N/A
Operating Margin
N/A
Profit Margin
N/A
Debt to Equity
0.44
Operating Cash Flow
-$4M
Beta
0.45
Next Earnings
N/A
Ex-Dividend
N/A
Next Dividend
N/A
DCOY Overview
Salarius Pharmaceuticals, Inc. focuses on advancing the peptide conjugate therapeutics through its Immediate Peptide/PPMO/P-PROTAC Alpha-helical Conjugate Technology (IMP3ACT) platform that reduces the complexity of drug development and manufacturing. Its IMP3ACT platform leverages machine learning and artificial intelligence tools alongside synthesis techniques to engineer, optimize, and manufacture peptide conjugates targeting various unmet medical needs. The company focuses on building a portfolio of peptide conjugate therapeutics focusing on infectious diseases and oncology. Salarius Pharmaceuticals, Inc. is based in Houston, Texas.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine DCOY's potential to beat the market
DSell
- Stocks with a Zen Rating of Sell (D) had an average loss of -4.50% per year. Learn More
Zen Rating Component Grades
C
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Industry: Biotech
Industry Rating
F
DCOY
Ranked#337 of 490
Ranked#337 of 490
Top Ranked Stocks in Industry
| Name / Ticker | Price | Zen Rating |
|---|---|---|
| $18.71 | A | |
| $161.13 | A | |
| $6.10 | A |
Be the first to know about important DCOY news, forecast changes, insider trades & much more!
DCOY News
Overview
Due Diligence Score
–
Industry Average (24)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how DCOY scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
DCOY is unprofitable, so we are unable to calculate its intrinsic value according to an updated version of Benjamin Graham's Formula from "The Intelligent Investor"
Below Benjamin Graham Formula Value Valuation
DCOY is good value based on its book value relative to its share price (1.13x), compared to the US Biotechnology industry average (5.49x)
P/B vs Industry Valuation
DCOY is unprofitable, so we... subscribe to Premium to read more.
PEG Value Valuation
There are 30 more DCOY due diligence checks available for Premium users.
Valuation
DCOY price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-0.02x
Industry
176.2x
Market
45.1x
DCOY price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
1.13x
Industry
5.49x
DCOY is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
DCOY's financial health
Profit margin
Revenue
$0.0
Net Income
-$873.5k
Profit Margin
0%
DCOY's cash burn is expected... subscribe to Premium to read more.
Interest Coverage Financials
Assets to liabilities
Assets
$6.1M
Liabilities
$1.8M
Debt to equity
0.44
DCOY's short-term assets ($6.06M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
DCOY's short-term assets ($6.06M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
DCOY's debt has increased relative... subscribe to Premium to read more.
Shrinking Debt Financials
DCOY's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$1.6M
Investing
$0.0
Financing
$5.9M
DCOY's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
DCOY vs Biotech Stocks
Decoy Therapeutics Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.